A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).

P, Abrams; M, Speakman; M, Stott; D, Arkell; R, Pocock

doi:10.1046/j.1464-410x.1997.00380.x

Public

A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).

Shared by NobleBlocks on Oct 1, 1997 • 12:00 AM UTC

Authors:

Abrams P

Speakman M

Stott M

Abstract

Objective To evaluate the efficacy and safety in a dose-ranging study of tamsulosin (once-daily) as a modified-release formulation compared with placebo in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and to establish the optimum dosage for ph...

Discussions